DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma

Oncotarget

Volumn 6, Issue 4, 2015, Pages 2193-2205

  Weygant, Nathaniel ^a   Qu, Dongfeng ^a,b,c   May, Randal ^a,b   Tierney, Ryan M ^a   Berry, William L ^a   Zhao, Lichao ^a   Agarwal, Shweta ^a   Chandrakesan, Parthasarathy ^a   Chinthalapally, Harisha R ^a   Murphy, Nicholas T ^a   Li, James D ^a   Sureban, Sripathi M ^a,b,c   Schlosser, Michael J ^d   Tomasek, James J ^a   Houchen, Courtney W ^a,b,c,d  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Peggy and Charles Stephenson Oklahoma Cancer Institute   (United States)

^d COARE Biotechnology ^*  (United States)

Author keywords

DCLK1; EMT; Focal adhesion; Renal carcinoma; Tumor stem cell

Indexed keywords

DOUBLECORTIN; MESSENGER RNA; PROTEIN ANTIBODY; PROTEIN DCLK1; SMALL INTERFERING RNA; TUMOR MARKER; UNCLASSIFIED DRUG; DCLK1 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE;

ARTICLE; CANCER STAGING; CANCER STEM CELL; CELL INVASION; CELL MIGRATION; CLONOGENESIS; COLORECTAL CANCER; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FOCAL ADHESION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PLURIPOTENT STEM CELL; REGULATORY MECHANISM; CELL MOTION; DNA METHYLATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; KIDNEY TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL MOVEMENT; DNA METHYLATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FOCAL ADHESIONS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASTIC STEM CELLS; PROMOTER REGIONS, GENETIC; PROTEIN-SERINE-THREONINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

EID: 84922983516     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3059     Document Type: Article

References (39)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1):11-30.
2. Krabbe LM, Westerman ME, Bagrodia A, Gayed BA, Darwish OM, Haddad AQ, Khalil D, Kapur P, Sagalowsky AI, Lotan Y and Margulis V. Dysregulation of beta-catenin is an independent predictor of oncological outcomes in patients with clear cell renal cell carcinoma. J Urol. 2013.
3. Walsh N, Larkin A, Kennedy S, Connolly L, Ballot J, Ooi W, Gullo G, Crown J, Clynes M and O'Driscoll L. Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma. BMC Urol. 2009; 9:6.
4. Prasad SR, Humphrey PA, Catena JR, Narra VR, Srigley JR, Cortez AD, Dalrymple NC and Chintapalli KN. Common and uncommon histologic subtypes of renal cell carcinoma: imaging spectrum with pathologic correlation. Radiographics. 2006; 26(6):1795-1806; discussion 1806-1710.
5. Shinojima T, Oya M, Takayanagi A, Mizuno R, Shimizu N and Murai M. Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha. Carcinogenesis. 2007; 28(3):529-536.
6. Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, Yu H, Kabbinavar FF, Pantuck AJ and Belldegrun AS. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res. 2007; 13(24):7388-7393.
7. Harada K, Miyake H, Kusuda Y and Fujisawa M. Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: impact on prognostic outcomes in patients undergoing radical nephrectomy. BJU Int. 2012; 110(11 Pt C):E1131-1137.
8. Philip B, Ito K, Moreno-Sanchez R and Ralph SJ. HIF expression and the role of hypoxic microenvironments within primary tumours as protective sites driving cancer stem cell renewal and metastatic progression. Carcinogenesis. 2013; 34(8):1699-1707.
9. Nakanishi Y, Seno H, Fukuoka A, Ueo T, Yamaga Y, Maruno T, Nakanishi N, Kanda K, Komekado H, Kawada M, Isomura A, Kawada K, Sakai Y, Yanagita M, Kageyama R, Kawaguchi Y, et al. Dclk1 distinguishes between tumor and normal stem cells in the intestine. Nature genetics. 2013; 45(1):98-9103.
10. Christoph Benedikt Westphalen MQ, Daniel Worthley, Samuel Asfaha, Helen Remotti, Kenneth P. Olive, and Timothy C. Wang. (2012). Dclk1 labels quiescent pancreatic progenitor and cancer initiating cells. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research. (Chicago, IL: AACR).
11. Bailey JM, Alsina J, Rasheed ZA, McAllister FM, Fu YY, Plentz R, Zhang H, Pasricha PJ, Bardeesy N, Matsui W, Maitra A and Leach SD. DCLK1 Marks a Morphologically Distinct Subpopulation of Cells with Stem Cell Properties in Pre-invasive Pancreatic Cancer. Gastroenterology. 2013.
12. Sureban SM, May R, Qu D, Weygant N, Chandrakesan P, Ali N, Lightfoot SA, Pantazis P, Rao CV, Postier RG and Houchen CW. DCLK1 Regulates Pluripotency and Angiogenic Factors via microRNA-Dependent Mechanisms in Pancreatic Cancer. PloS one. 2013; 8(9):e73940.
13. Li L and Bellows CF. Doublecortin-like kinase 1 exhibits cancer stem cell-like characteristics in a human colon cancer cell line. Chin J Cancer Res. 2013; 25(2):134-142.
14. Westphalen CB, Asfaha S, Hayakawa Y, Takemoto Y, Lukin DJ, Nuber AH, Brandtner A, Setlik W, Remotti H, Muley A, Chen X, May R, Houchen CW, Fox JG, Gershon MD, Quante M, et al. Long-lived intestinal tuft cells serve as colon cancer-initiating cells. The Journal of clinical investigation. 2014; 124(3):1283-1295.
15. Sansom OJ, Griffiths DF, Reed KR, Winton DJ and Clarke AR. Apc deficiency predisposes to renal carcinoma in the mouse. Oncogene. 2005; 24(55):8205-8210.
16. Lenburg ME, Liou LS, Gerry NP, Frampton GM, Cohen HT and Christman MF. Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC Cancer. 2003; 3:31.
17. Cancer Genome Atlas Research N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013; 499(7456):43-49.
18. Beroukhim R, Brunet JP, Di Napoli A, Mertz KD, Seeley A, Pires MM, Linhart D, Worrell RA, Moch H, Rubin MA, Sellers WR, Meyerson M, Linehan WM, Kaelin WG, Jr. and Signoretti S. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 2009; 69(11):4674-4681.
19. Lewandowska J and Bartoszek A. DNA methylation in cancer development, diagnosis and therapy-multiple opportunities for genotoxic agents to act as methylome disruptors or remediators. Mutagenesis. 2011; 26(4):475-487.
20. Andresen K, Boberg KM, Vedeld HM, Honne H, Hektoen M, Wadsworth CA, Clausen OP, Karlsen TH, Foss A, Mathisen O, Schrumpf E, Lothe RA and Lind GE. Novel target genes and a valid biomarker panel identified for cholangiocarcinoma. Epigenetics. 2012; 7(11):1249-1257.
21. Vedeld HM, Skotheim RI, Lothe RA and Lind GE. The recently suggested intestinal cancer stem cell marker is an epigenetic biomarker for colorectal cancer. Epigenetics. 2014; 9(3).
22. Hanley JA and McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983; 148(3):839-843.
23. Rosenbloom KR, Sloan CA, Malladi VS, Dreszer TR, Learned K, Kirkup VM, Wong MC, Maddren M, Fang R, Heitner SG, Lee BT, Barber GP, Harte RA, Diekhans M, Long JC, Wilder SP, et al. ENCODE data in the UCSC Genome Browser: year 5 update. Nucleic acids research. 2013; 41(Database issue):D56-63.
24. Harvard BIoMa. (2014). Broad Institute TCGA Genome Data Analysis Center (2014): Correlation between mRNA expression and DNA methylation.
25. Chen D, Gassenmaier M, Maruschke M, Riesenberg R, Pohla H, Stief CG, Zimmermann W and Buchner A. Expression and prognostic significance of a comprehensive epithelial-mesenchymal transition gene set in renal cell carcinoma. J Urol. 2014; 191(2):479-486.
26. Katagiri A, Watanabe R and Tomita Y. E-cadherin expression in renal cell cancer and its significance in metastasis and survival. Br J Cancer. 1995; 71(2):376-379.
27. Chandrakesan P, Weygant N, May R, Qu D, Chinthalapally HR, Sureban SM, Ali N, Lightfoot SA, Umar S and Houchen CW. DCLK1 facilitates intestinal tumor growth via enhancing pluripotency and epithelial mesenchymal transition. Oncotarget. 2014.
28. Sureban SM, May R, Lightfoot SA, Hoskins AB, Lerner M, Brackett DJ, Postier RG, Ramanujam R, Mohammed A, Rao CV, Wyche JH, Anant S and Houchen CW. DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer Res. 2011; 71(6):2328-2338.
29. Sureban SM, May R, Weygant N, Qu D, Chandrakesan P, Bannerman-Menson E, Ali N, Pantazis P, Westphalen CB, Wang TC and Houchen CW. XMD8-92 inhibits pancreatic tumor xenograft growth via DCLK1-dependent mechanism. Cancer letters. 2014.
30. Weygant N, Qu D, Berry WL, May R, Chandrakesan P, Owen DB, Sureban SM, Ali N, Janknecht R and Houchen CW. Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1. Molecular cancer. 2014; 13(1):103.
31. Berggard T, Arrigoni G, Olsson O, Fex M, Linse S and James P. 140 mouse brain proteins identified by Ca2+-calmodulin affinity chromatography and tandem mass spectrometry. Journal of proteome research. 2006; 5(3):669-687.
32. Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT, Maitland A, Mostafavi S, Montojo J, Shao Q, Wright G, Bader GD, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic acids research. 2010; 38(Web Server issue):W214-220.
33. Zuberi K, Franz M, Rodriguez H, Montojo J, Lopes CT, Bader GD and Morris Q. GeneMANIA prediction server 2013 update. Nucleic acids research. 2013; 41(Web Server issue):W115-122.
34. Ueda K, Ogasawara S, Akiba J, Nakayama M, Todoroki K, Ueda K, Sanada S, Suekane S, Noguchi M, Matsuoka K and Yano H. Aldehyde dehydrogenase 1 identifies cells with cancer stem cell-like properties in a human renal cell carcinoma cell line. PloS one. 2013; 8(10):e75463.
35. Wang K, Chen X, Zhan Y, Jiang W, Liu X, Wang X and Wu B. Increased expression of ALDH1A1 protein is associated with poor prognosis in clear cell renal cell carcinoma. Medical oncology. 2013; 30(2):574.
36. Wiklund F, Tretli S, Choueiri TK, Signoretti S, Fall K and Adami HO. Risk of bilateral renal cell cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009; 27(23):3737-3741.
37. Watanabe K, Akimoto Y, Yugi K, Uda S, Chung J, Nakamuta S, Kaibuchi K and Kuroda S. Latent process genes for cell differentiation are common decoders of neurite extension length. Journal of cell science. 2012; 125(Pt 9):2198-2211.
38. Chen L, Endler A and Shibasaki F. Hypoxia and angiogenesis: regulation of hypoxia-inducible factors via novel binding factors. Experimental & molecular medicine. 2009; 41(12):849-857.
39. Matsumoto N, Pilz DT and Ledbetter DH. Genomic structure, chromosomal mapping, and expression pattern of human DCAMKL1 (KIAA0369), a homologue of DCX (XLIS). Genomics. 1999; 56(2):179-183.